Armata Pharmaceuticals, Inc.ARMPNYSE
Loading
Year-over-year research & development expense growth
Percentile
P28
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -8.91% |
| Q2 2025 | 17.77% |
| Q1 2025 | -35.75% |
| Q4 2024 | -10.91% |
| Q3 2024 | 11.92% |
| Q2 2024 | 5.73% |
| Q1 2024 | 1.11% |
| Q4 2023 | -0.63% |
| Q3 2023 | -3.40% |
| Q2 2023 | -14.00% |
| Q1 2023 | 0.37% |
| Q4 2022 | 13.92% |
| Q3 2022 | -6.87% |
| Q2 2022 | 12.36% |
| Q1 2022 | 66.76% |
| Q4 2021 | -14.43% |
| Q3 2021 | 7.67% |
| Q2 2021 | 20.11% |
| Q1 2021 | -12.65% |
| Q4 2020 | 22.48% |
| Q3 2020 | 53.55% |
| Q2 2020 | -3.71% |
| Q1 2020 | 64.87% |
| Q4 2019 | -44.75% |
| Q3 2019 | -1.85% |
| Q2 2019 | 105.89% |
| Q1 2019 | 8.65% |
| Q4 2018 | 280.89% |
| Q3 2018 | -78.66% |
| Q2 2018 | 15.57% |
| Q1 2018 | 34.31% |
| Q4 2017 | 231.48% |
| Q3 2017 | -173.36% |
| Q2 2017 | -24.16% |
| Q1 2017 | 85.79% |
| Q4 2016 | -51.54% |
| Q3 2016 | 33.36% |
| Q2 2016 | -37.32% |
| Q1 2016 | 62.96% |
| Q4 2015 | 66.90% |